QEII redevelopment tender includes possibility of a new hospital
The provincial health authority issued a tender on Thursday for master planning services as part of the continued redevelopment of the QEII Health Sciences Centre, work that could include the development of a new hospital building.
The tender calls for project management and architectural services for further redevelopment of buildings on the campus that includes the Halifax Infirmary and the series of buildings around the Victoria General Hospital.
The work would also include, "if deemed required by Nova Scotia Health and the province, the development of an additional QEII site (location yet to be determined)," according to the tender.
The initial term of the agreement would be for two years, with the health authority having the ability to extend it for an additional year. Submissions are due by May 15.
"The objective of this RFP [request for proposal] is to establish a multi-site master plan, resulting in a clear understanding of specific projects that addresses failing/inadequate infrastructure and the changing health care needs of the local community and beyond," tender documents say.
Broad scope of work
The master planning work is to be delivered in two parts, the first by December and the second by Nov. 1, 2026.
The winning bidder will be tasked with an extensive amount of planning that runs the gamut of services provided by the QEII, including: ambulatory care and outpatient clinics; minor procedures and endoscopy; biomedical engineering; cancer care; critical care unit; diagnostic imaging; environmental services; facilities management; heart health; laboratory services; medical device reprocessing; medical/surgical/rehabilitation/mental health inpatients; morgue; nutrition and food services; pharmacy; regional tissue bank; security services; supply chain logistics; and volunteer services.
The work also includes a technical building assessment, "which would evaluate and report on the physical condition of the facility, including below-grade tunnels, in order to determine if it has value for future use or requires replacement at a future date." The assessment will also consider the implications of deferring capital investment.
In considering the options for development, the report must include: existing facility building constraints; new physical plant requirements; parking demand and transportation impact studies.
If the province and health authority determine that master planning for an additional QEII site is needed, that work would require a site selection and land assessment report and a master plan report.
First major redevelopment contract signed
A former Liberal government started the redevelopment process in 2015, but Premier Tim Houston announced an overhauled version in late 2022 because the Liberal plan could no longer accommodate the population explosion the province experienced following the start of the COVID-19 pandemic.
The Progressive Conservative government signed a long-awaited contract earlier this year for the first phase of the Halifax Infirmary redevelopment, work that includes a 14-storey acute care tower with patient beds and operating theatres, an intensive care unit and a new emergency department.
The $7.4-billion deal includes construction costs and the operation and maintenance of the site for 30 years.
Meanwhile, the life of the Victoria General Hospital continues to be extended until the redevelopment work can be completed. The ailing site has a litany of issues, including water that is not safe for drinking and elevators that do not work.
The tender documents released Thursday include a nod to the ongoing trade dispute with the U.S. government.
In the section that deals with eligibility, it notes that "the province reserves the right to exclude bids from jurisdictions where unfair trade barriers, including but not limited to tariffs, have been imposed, or as may be justified by national security or similar exceptions."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Japan Forward
an hour ago
- Japan Forward
AI Tool 'KIBIT': A Game Changer in New Drug Development
このページを 日本語 で読む The COVID-19 pandemic reminded the world of the importance of drug discovery. However, modern drug discoveries require massive financial investment. Meanwhile, the use of artificial intelligence for AI drug discovery is gaining attention as a way to control soaring pharmaceutical prices. And a Japanese-made AI tool named 'KIBIT' is about to open up a new stage in this field. President Donald Trump issued executive orders in April and May mandating the reduction of domestic drug prices in the United States. Accompanying White House fact sheets refer to the high cost Americans pay for prescriptions, which is 2.78 times higher than the OECD average. Prescription costs are also 3.47 times higher than in Japan. Trump sees these high costs to consumers as a serious issue. In Japan, a national drug pricing system sets medication prices, enabling access to affordable treatments due to governmental oversight. In contrast, US pharmaceutical companies can set prices freely. This often results in higher charges than in other countries. Following his May 12 executive order, Trump stated that his orders would cut prices by 59% to as much as 90% to align with the levels of other countries. This could potentially result in significant revenue losses for the pharmaceutical industry. In the case of Japan, major pharmaceutical companies such as Takeda Pharmaceutical Company Limited and Astellas Pharma Inc earn over 30% of their revenue from the US. According to his comments, the President could impose additional tariffs on foreign-manufactured drugs if prices are not reduced. In the search for new drugs and treatments (Screenshot, ©FRONTEO Inc) One major reason for rising drug prices is the increasing cost of research and development. The average R&D spending by Japanese pharmaceutical companies rose from ¥30.2 billion JPY ($298.7 million USD) in 1993 to 163.3 billion ($1.13 billion) in 2019 — a 5.4-fold increase over 26 years. US companies saw an even sharper rise, from $841 million (¥121.1 billion) to $7.449 billion (¥1.0725 trillion). That marked an 8.8-fold increase. Moreover, investing in R&D doesn't guarantee success. The probability of developing a successful drug in Japan dropped from 1 in 13,000 two decades ago to 1 in 23,000 recently. Despite the increasing costs, results are scarce. Consequently, the R&D-to-revenue ratio rose from about 10% in 1993 to around 18% in 2019 in both countries. Introducing KIBIT. (Screenshot ©FRONTEO Inc) AI is being eyed as a solution to reduce R&D costs by dramatically cutting time and expenses. Drug development involves four stages: Basic research & target identification Compound optimization Preclinical trials and Clinical trials. Many AI vendors are involved in drug discovery. In particular, they focus on reducing costs in the third (preclinical) and fourth (clinical) stages. However, most companies have yet to tackle the critical first stage — target identification. Introducing KIBIT. (Screenshot, ©FRONTEO Inc) The first enterprise to address this initial stage is the Japanese company FRONTEO. Utilizing its proprietary natural language processing AI engine KIBIT, the company analyzes vast medical and pharmaceutical literature to generate innovative drug ideas that researchers may not have considered. Human thinking is inherently biased. The more experienced a researcher is, the more difficult it becomes to identify novel molecular targets. Stated another way, the bias of experience often blocks new ideas. KIBIT, however, is free from such biases. It identifies new molecular targets that might be effective against specific diseases. To do so, it analyzes vast amounts of academic literature. It can even derive specific hypotheses. Furthermore, KIBIT can identify and suggest highly disease-relevant target molecules that are not explicitly mentioned in the literature. This significantly enhances drug discovery potential. How KIBIT works. (Screenshot, ©FRONTEO Inc) Only a few countries have the capacity to develop new drugs. In 2024, among newly approved pharmaceuticals in Japan, the US, and Europe, the US led with 143 products. Japan followed with just 12, roughly equal to the United Kingdom's 10. According to the statistics "Nationalities of companies creating the top 100 drugs in the world by sales (2022),": United States – 52 United Kingdom – 10 Switzerland – 9 Germany – 8 Denmark – 8 Japan – 7 Most countries, other than the US, struggle to produce blockbuster drugs. In this context, hopes are high for FRONTEO's KIBIT. If it can consistently generate innovative new drugs efficiently, it may help deliver affordable medicines to those in need, without Mr Trump's intervention. FRONTEO's AI drug discovery service, utilizing KIBIT, is already being adopted by several major pharmaceutical companies. Those leveraging KIBIT to create new drugs could become game changers in the industry. This article is contributed by FRONTEO Inc, a supporting member of JAPAN Forward. (Read the report in Japanese.) Author: FRONTEO Inc. このページを 日本語 で読む


Global News
a day ago
- Global News
RFK Jr. removes all 17 members of U.S. vaccine advisory panel
U.S. Health Secretary Robert F. Kennedy Jr. on Monday removed every member of a scientific committee that advises the Centers for Disease Control and Prevention on how to use vaccines and pledged to replace them with his own picks. Major physicians and public health groups criticized the move to oust all 17 members of the Advisory Committee on Immunization Practices. Kennedy, who was one of the nation's leading anti-vaccine activists before becoming the nation's top health official, has not said who he would appoint to the panel, but said it would convene in just two weeks in Atlanta. Although it's typically not viewed as a partisan board, the Biden administration had installed the entire committee. 'Without removing the current members, the current Trump administration would not have been able to appoint a majority of new members until 2028,' Kennedy wrote in a Wall Street Journal opinion piece. 'A clean sweep is needed to re-establish public confidence in vaccine science.' Story continues below advertisement Kennedy said the committee members had too many conflicts of interest. Committee members routinely disclose any possible conflicts at the start of public meetings. Dr. Georges Benjamin, executive director of the American Public Health Association, called Kennedy's mass ouster 'a coup.' 'It's not how democracies work. It's not good for the health of the nation,' Benjamin told The Associated Press. 0:37 RFK announces COVID vaccine removal from immunization schedule for pregnant women and children Benjamin said the move raises real concerns about whether future committee members will be viewed as impartial. He added that Kennedy is going against what he told lawmakers and the public, and the public health association plans to watch Kennedy 'like a hawk.' Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy 'He is breaking a promise,' Benjamin said. 'He said he wasn't going to do this.' Dr. Bruce A. Scott, president of the American Medical Association, called the committee a trusted source of science- and data-driven advice and said Kennedy's move, coupled with declining vaccination rates across the country, will help drive an increase in vaccine-preventable diseases. Story continues below advertisement 'Today's action to remove the 17 sitting members of ACIP undermines that trust and upends a transparent process that has saved countless lives,' Scott said in a statement. Republican Sen. Bill Cassidy of Louisiana, a doctor who had expressed reservations about Kennedy's nomination but voted to install him as the nation's health secretary nonetheless, said he had spoken with Kennedy moments after the announcement. 'Of course, now the fear is that the ACIP will be filled up with people who know nothing about vaccines except suspicion,' Cassidy said in a social media post. 'I've just spoken with Secretary Kennedy, and I'll continue to talk with him to ensure this is not the case.' 9:34 RFK Jr. and Elizabeth Warren get into heated debate over vaccine question at confirmation hearing The committee had been in a state of flux since Kennedy took over. Its first meeting this year had been delayed when the U.S. Department of Health and Human Services abruptly postponed its February meeting. Story continues below advertisement During Kennedy's confirmation, Cassidy had expressed concerns about preserving the committee, saying he had sought assurances that Kennedy would keep the panel's current vaccine recommendations. Kennedy did not stick to that. He recently took the unusual step of changing COVID-19 recommendations without first consulting the advisers. The webpage that featured the committee's members was deleted Monday evening, shortly after Kennedy's announcement.


Winnipeg Free Press
a day ago
- Winnipeg Free Press
RFK Jr. ousts entire CDC vaccine advisory committee
WASHINGTON (AP) — Health Secretary Robert F. Kennedy Jr. on Monday removed every member of a scientific committee that advises the Centers for Disease Control and Prevention on how to use vaccines and pledged to replace them with his own picks. The 17-member Advisory Committee on Immunization Practices had been in a state of flux since Kennedy took over. Its first meeting this year had been delayed when the U.S. Department of Health and Human Services abruptly postponed its February meeting. Kennedy, who was one of the nation's leading anti-vaccine activists before becoming the nation's top health official, recently took the unusual step of changing COVID-19 recommendations without first consulting the panel. Kennedy, in a Wall Street Journal opinion piece, said the committee members had too many conflicts of interest. Committee members routinely disclose any possible conflicts at the start of public meetings. Wednesdays Columnist Jen Zoratti looks at what's next in arts, life and pop culture. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.